| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Schedule Of Restructuring And Related Costs [Table] | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net loss | ||||||
-60,826 | -38,893 | - | - | - | - | - |
Net loss | ||||||
- | - | -22,340 | -18,699 | -12,090 | -5,187 | 13,060 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Acquired in-process research and development | ||||||
6,567 | - | - | - | - | - | - |
Deferred taxes | ||||||
-1,309 | - | - | - | - | - | - |
Stock-based compensation | ||||||
8,082 | 4,144 | 2,714 | 2,759 | 2,187 | 2,037 | 1,701 |
President and CEO contributed services | ||||||
- | - | - | - | - | - | 46 |
Non-cash interest expense | ||||||
248 | 59 | 20 | 27 | 35 | 150 | 121 |
Accretion on debt securities available for sale, net | ||||||
583 | 237 | -129 | -266 | - | - | - |
Change in fair value of warrant liability, purchase rights and warrant purchase rights | ||||||
- | - | - | - | - | -2,327 | - |
Change in fair value of warrant liability, purchase rights and warrant purchase rights | ||||||
- | - | - | - | - | - | -16,896 |
Depreciation | ||||||
96 | 71 | 37 | 35 | 18 | 1 | - |
Change in assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
454 | 150 | 800 | -278 | 264 | 224 | 5 |
Accounts payable | ||||||
-2,846 | 2,049 | 725 | -575 | 509 | -0 | 269 |
Accrued interest on convertible notes related parties | ||||||
- | - | - | - | - | -2 | - |
Accrued interest on convertible notes related parties | ||||||
- | - | - | - | - | - | 2 |
Accrued expenses | ||||||
6,041 | 3,099 | 290 | 759 | 291 | 776 | -6 |
Net cash used in operating activities | ||||||
-44,984 | -29,857 | -19,222 | - | - | - | - |
Net cash used in operating activities | ||||||
- | - | - | -15,147 | -9,311 | -4,775 | -1,706 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Acquisitions of property and equipment | ||||||
9 | 262 | 24 | 11 | 86 | 14 | - |
Purchases of marketable securities | ||||||
57,768 | 59,731 | 35,095 | 16,048 | 12,950 | - | - |
Sales of marketable securities | ||||||
75,645 | 36,659 | 24,922 | 15,835 | - | - | - |
Net cash provided by investing activities | ||||||
18,476 | -23,335 | -10,197 | - | - | - | - |
Net cash provided by investing activities | ||||||
- | - | - | -225 | -13,036 | -14 | - |
Proceeds from issuance of common stock and exercise of options | ||||||
- | - | - | - | 28,505 | - | - |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Proceeds from issuance of common stock, net of issuance costs | ||||||
7,891 | 81,837 | 37,469 | 12,649 | - | 10,055 | - |
Deferred offering costs paid in cash | ||||||
- | - | 165 | - | - | - | - |
Proceeds from convertible notes payable - related parties | ||||||
- | - | - | - | - | - | 170 |
Proceeds from issuance of restricted common stock | ||||||
- | - | - | - | - | - | -7 |
Proceeds from exercise of stock options | ||||||
1,162 | - | - | - | - | - | - |
Proceeds from employee stock purchase plan | ||||||
194 | 85 | - | - | - | - | - |
Borrowings under credit facility, net | ||||||
- | - | - | - | - | 1,395 | 1,000 |
Extinguishment of long-term debt | ||||||
- | 1,395 | - | - | - | 1,395 | 104 |
Proceeds from employee stock purchase plan | ||||||
- | - | 125 | 89 | - | - | - |
Proceeds from long-term debt | ||||||
14,450 | - | - | - | - | - | - |
Debt issuance costs paid in cash | ||||||
123 | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||
23,575 | 80,526 | 37,428 | - | - | - | - |
NET DECREASE IN CASH AND CASH EQUIVALENTS | ||||||
-2,931 | 27,334 | - | - | - | - | - |
Fair value warrants in connection with credit facility | ||||||
- | - | - | - | - | - | 177 |
Offeratory costs in connection with Series B redeemable convertible preferred stock issuance in accrued expenses | ||||||
- | - | - | - | - | - | 17 |
Deferred offering costs not yet paid | ||||||
- | - | - | - | - | 14 | 394 |
Accretion of redeemable convertible preferred stock | ||||||
- | - | - | - | - | 333 | 822 |
SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: | ||||||
Deferred offering costs paid in cash | ||||||
- | - | - | - | 36 | - | 78 |
Net proceeds from issuance of Series B redeemable convertible preferred stock | ||||||
- | - | - | - | - | - | 2,750 |
Net cash provided by financing activities | ||||||
- | - | - | 12,738 | 28,469 | 10,055 | 3,745 |
NET (DECREASE)/INCREASE IN CASH | ||||||
- | - | 8,008 | -2,633 | 6,121 | 5,264 | 2,038 |
Interest | ||||||
- | - | - | 78 | 74 | 96 | 34 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||
Cash paid during the period for interest | ||||||
238 | 88 | 91 | - | - | - | - |
Conversion of notes payable | ||||||
- | - | - | - | - | 170 | - |
Net exercise of warrants into common stock | ||||||
- | - | - | - | - | 1,191 | - |
Allocation of fair value of investor purchase rights to redeemable convertible preferred stock | ||||||
- | - | - | - | - | - | 6,264 |
Warrants issued to underwriter in initial public offering | ||||||
- | - | - | - | - | 315 | - |
Exercise of Series B warrant purchase rights into warrants | ||||||
- | - | - | - | - | - | 1,793 |
Helio Vision, Inc [Member] | ||||||
Acquired in-process research and development | ||||||
6,600 | - | - | - | - | - | - |
Cash acquired in Helio asset acquisition | ||||||
609 | - | - | - | - | - | - |
Assets acquired | ||||||
75 | - | - | - | - | - | - |
Liabilities acquired | ||||||
637 | - | - | - | - | - | - |
Fair value of securities issued | ||||||
4,944 | - | - | - | - | - | - |